DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

Phase 3

Completed

Conditions: Familial Hypercholesterolemia

Interventions: Biological: Evolocumab

First Posted Date: 2015-12-09

Last Posted Date: 2024-05-29

Lead Sponsor: Amgen

Target Recruit Count: 163

Registration Number: NCT02624869

Locations: 🇬🇧
Research Site, Birmingham, United Kingdom

ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line

Completed

Conditions: Metastatic Colorectal Cancer

First Posted Date: 2015-12-09

Last Posted Date: 2021-01-22

Lead Sponsor: Amgen

Target Recruit Count: 296

Registration Number: NCT02624895

Locations: 🇮🇹
Research Site, Viterbo, Italy

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study

Phase 3

Completed

Conditions: Friedreich's Ataxia

Interventions: Drug: Interferon γ-1b

First Posted Date: 2015-11-01

Last Posted Date: 2024-12-19

Lead Sponsor: Amgen

Target Recruit Count: 86

Registration Number: NCT02593773

Locations: 🇺🇸
University of Florida - Clinical Research Center, Gainesville, Florida, United States
🇺🇸
University of Iowa Children's Hospital, Iowa City, Iowa, United States
🇺🇸
University of California, Los Angeles Neurology Clinic, Los Angeles, California, United States

and more 1 locations

Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Men and Women

Interventions: Device: etanercept (ENBREL®) via auto-injector device
Other: Etanercept (ENBREL®) via Manual injection

First Posted Date: 2015-10-28

Last Posted Date: 2015-10-28

Lead Sponsor: Amgen

Target Recruit Count: 36

Registration Number: NCT02588534

Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Other: Tetracycline
Other: Demeclocycline
Procedure: Total Hip Replacement

First Posted Date: 2015-10-15

Last Posted Date: 2019-04-26

Lead Sponsor: Amgen

Target Recruit Count: 6

Registration Number: NCT02576652

Locations: 🇺🇸
Helen Hayes Hospital, West Haverstraw, New York, United States
🇺🇸
Research Site, West Haverstraw, New York, United States

A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Apremilast

First Posted Date: 2015-10-15

Last Posted Date: 2020-05-07

Lead Sponsor: Amgen

Target Recruit Count: 42

Registration Number: NCT02576678

Locations: 🇩🇪
Muenster University Hospital (Universitätsklinikum Muenster), Munster, Germany
🇩🇪
Kinderkrankenhaus Wilhelmstift, Dermatologie, Hamburg, Germany
🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

and more 15 locations

Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581

Phase 1

Completed

Conditions: Schizophrenia or Schizoaffective Disorder

Interventions: Drug: Placebo
Drug: AMG 581

First Posted Date: 2015-10-05

Last Posted Date: 2015-10-23

Lead Sponsor: Amgen

Target Recruit Count: 70

Registration Number: NCT02567370

Locations: 🇺🇸
Research Site, Glendale, California, United States

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: AMG 224

First Posted Date: 2015-09-28

Last Posted Date: 2024-02-01

Lead Sponsor: Amgen

Target Recruit Count: 42

Registration Number: NCT02561962

Locations: 🇦🇺
Research Site, Prahran, Victoria, Australia

To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: PACAP-38 Challenge Agent
Drug: Placebo
Drug: Erenumab

First Posted Date: 2015-09-07

Last Posted Date: 2019-06-03

Lead Sponsor: Amgen

Target Recruit Count: 35

Registration Number: NCT02542605

Locations: 🇳🇱
Research Site, Leiden, Netherlands

A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

Phase 1

Terminated

Conditions: Myelodysplastic Syndrome
Minimal Residual Disease Positive AML
Relapsed/Refractory AML

Interventions: Drug: AMG 330

First Posted Date: 2015-08-11

Last Posted Date: 2024-07-31

Lead Sponsor: Amgen

Target Recruit Count: 95

Registration Number: NCT02520427

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇳🇱
Research Site, Amsterdam, Netherlands
🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy